Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT02379377

18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

Led by M.D. Anderson Cancer Center · Updated on 2026-03-09

110

Participants Needed

1

Research Sites

275 weeks

Total Duration

On this page

Sponsors

M

M.D. Anderson Cancer Center

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose liver cancer and find out how far the disease has spread.

CONDITIONS

Official Title

18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of hepatocellular carcinoma (HCC) meeting specific imaging or pathology criteria including LI-RADS features, AFP levels, or biopsy confirmation
  • Diagnosis of benign liver tumor with suggestive imaging findings and prior MRI or CT within 8 weeks
  • Diagnosis of malignant non-HCC liver tumor confirmed by biopsy or imaging and prior MRI or CT within 8 weeks
  • Diagnosis of oligometastatic solid tumors in specified sites undergoing local therapy
  • Completion of conventional imaging and staging including MRI or CT before investigational PET studies
  • For HCC patients, eligibility for liver resection, orthotopic liver transplant (OLT), or Y90 radioembolization
Not Eligible

You will not qualify if you...

  • Under 18 years old
  • Not a candidate for liver resection surgery, OLT, or Y90 radioembolization despite having HCC or cholangiocarcinoma
  • Pregnant or breastfeeding without adequate birth control or negative pregnancy test prior to PET scans
  • Poorly controlled diabetes mellitus with fasting blood glucose level over 200 mg/dL
  • Known infiltrative variant of hepatocellular carcinoma (HCC)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

MD Anderson Cancer Center

Houston, Texas, United States, 77090

Actively Recruiting

Loading map...

Research Team

S

Simone S Krebs, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here